Skip to main content Skip to footer
Novakand Pharma
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Svenska
Start>News>Report>Interim>Yearend

Yearend

  • Interim Report Fourth Quarter 2024, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

    21 February 2025

  • Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

    23 February 2024

  • Interim Report Fourth Quarter 2022 January 1 – December 31 2022 Kancera AB (publ.), org.nr. 556806-8851

    23 February 2023

  • Interim report for fourth quarter 2021, 1 January – 31 December 2021 Kancera AB (publ.), org.nr. 556806-8851

    18 February 2022

  • Interim report for fourth quarter 2020, 1 January – 31 December 2020

    19 February 2021

  • Interim report for the fourth quarter 2019, 1 January – 31 December 2019 Kancera AB (publ.), org.nr. 556806-8851.

    2 March 2020

  • Year End Report Kancera AB (publ) 1st January – 31st December 2018

    6 March 2019

  • YEAR END REPORT KANCERA  AB (publ) 1st January – 31st December 2017

    20 February 2018

  • INTERIM REPORT FOR KANCERA AB (PUBL) Q4 2016. January 1st – December  31st 2016

    21 February 2017

  • Interim Report for Kancera AB (publ) Q4 2015, January 1 – December 31, 2015

    19 February 2016

+46 (0)8 5012 60 80Nanna Svarts väg 4, 171 65 Solna, Sweden

Content

  • Home
  • About us
  • Pipeline
  • Therapeutic areas
  • Investors

Shortcuts

  • Press Releases
  • Financial Reports
  • Financial Calendar
  • Website Policy

Copyright © 2026 Novakand AB. All Rights Reserved. Design by Clavis Communications